Alnylam Pharmaceuticals, Inc. (ALNY) Downgraded by Vetr Inc.

Alnylam Pharmaceuticals, Inc. (ALNY) Downgraded by Vetr Inc.


They currently have a $46.27 price target on the biopharmaceutical company's stock. Vetr 's target price points to a potential upside of 11.90% from the stock's previous close.



from Biotech News